Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Income from Continuing Operations: 2017-2025

Historic Income from Continuing Operations for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to -$79.1 million.

  • Autolus Therapeutics' Income from Continuing Operations rose 3.63% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 16.81%. This contributed to the annual value of -$220.7 million for FY2024, which is 5.89% down from last year.
  • As of Q3 2025, Autolus Therapeutics' Income from Continuing Operations stood at -$79.1 million, which was down 65.11% from -$47.9 million recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Income from Continuing Operations high stood at -$6.8 million for Q4 2021, and its period low was -$44.8 billion during Q3 2021.
  • Its 3-year average for Income from Continuing Operations is -$56.9 million, with a median of -$52.7 million in 2024.
  • As far as peak fluctuations go, Autolus Therapeutics' Income from Continuing Operations tumbled by 84,283.07% in 2021, and later surged by 99.90% in 2022.
  • Autolus Therapeutics' Income from Continuing Operations (Quarterly) stood at -$6.8 million in 2021, then slumped by 298.16% to -$27.0 million in 2022, then slumped by 186.04% to -$77.2 million in 2023, then skyrocketed by 64.23% to -$27.6 million in 2024, then increased by 3.63% to -$79.1 million in 2025.
  • Its Income from Continuing Operations stands at -$79.1 million for Q3 2025, versus -$47.9 million for Q2 2025 and -$70.2 million for Q1 2025.